Researchers from the Departments of Cell Biology and Medical Physiology at the University of Seville have identified that a high expression of the human protein VRK1 is associated with tumour aggressiveness and low survival among neuroblastoma patients.
Aggressive neuroblastoma is one of the most common solid childhood cancers and causes disproportionately high mortality in affected children.
Although advances have been made in recent years, the outlook for recovery in children affected by aggressive neuroblastoma remains low and a better understanding of this tumour's biology is needed in order to create new treatments and prognostic tools.
Researchers have characterised the function of VRK1 in neuroblastoma tumour cells and have determined that this protein is essential for tumour cell growth and proliferation.
"By studying the expression of this protein in tumours, we were able to identify a priori patients where tumour progression is going to be worse, even in groups where current tools do not predict that behaviour," notes Francisco M. Vega.
This study suggests that VRK1 works in conjunction with other oncogenes such as MYCN, which is heavily affected in this cancer, to boost tumour progression and make it more aggressive.
Therefore, the researchers suggest that inhibiting VRK1 could be a new strategy for cancer therapy in neuroblastoma. "VRK1 is a protein kinase.
These are some of the best targets for targeted cancer treatment, as we can potentially produce inhibitors in the laboratory that override their activity," explains Professor Vega.
Source: UNIVERSITY OF SEVILLE
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.